TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04899037

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
Study: NCT05520775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide (subcutaneous)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo
Description: Sham subcutaneous injection
Study: NCT05059132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The education only arm will receive information on the importance of general exercise following lung cancer treatment.
Study: NCT04983732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101-Intravenous
Description: 150 mg administered via the IV route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101-Subcutaneous
Description: 150 mg administered via the SC route
Study: NCT06403501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone
Description: Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
Study: NCT06236997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide, carboplatin(EC)
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Study: NCT05651737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sui App (SRK)
Description: The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sui App (SRK)
Description: The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification
Study: NCT05309889

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04379115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active tDCS + Active TUS
Description: Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham tDCS + Sham TUS
Description: Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes.
Study: NCT04783623

Intervention type: PROCEDURE
Intervention: Surgical endometrioma excision
Description: We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview

Intervention type: PROCEDURE
Intervention: Surgical endometrioma excision
Description: We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
Study: NCT05019547

Intervention type: BEHAVIORAL
Intervention: Determining Barriers and Facilitators of Physical Activity
Description: Determining Barriers and Facilitators of Physical Activity
Study: NCT05000684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004 in combination with toripalimab
Description: Usage and dosage: Inject 200mg once every 3 weeks
Study: NCT05638672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashi Baidu Granule
Description: Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monapiravir
Description: Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
Study: NCT05342441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QT graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST/Gr graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BPTB graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar.
Study: NCT06189781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, lidocaine, ropivacaine
Description: The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
Study: NCT06479486

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assigned Interventions
Description: warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
Study: NCT05088460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study: NCT05628350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No UPF controlled diet
Description: Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard UPF controlled diet
Description: Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
Study: NCT05089708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene Cream
Description: Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifarotene Vehicle Cream
Description: Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
Study: NCT02866266

Intervention type: OTHER
Intervention: Retrospective database review

Intervention type: OTHER
Intervention: Retrospective database review
Study: NCT04718389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294 (Depemokimab)
Description: GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: Mepolizumab will be provided in a single-use PFS.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: Benralizumab will be provided in a single-use PFS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be a sterile liquid formulation.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be a sterile liquid formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care (SoC)
Description: Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SoC)
Description: Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Syringes (PFS)
Description: PFS will include glass barrel with pre-staked needle and plunger.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-filled Syringes (PFS)
Description: PFS will include glass barrel with pre-staked needle and plunger.
Study: NCT06006078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Patient Facemask
Description: A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
Study: NCT05088460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study: NCT05564403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT05434546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone
Description: Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
Study: NCT06033443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Learning Group
Description: The experimental group is the group that receives nursing education based on collaborative learning.
Study: NCT06392815

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cu DOTATATE PET
Description: The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cu DOTATATE PET
Description: The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
Study: NCT05594524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Confident Athletes
Description: The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
Study: NCT06247826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
Study: NCT05051618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER-MS
Description: The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FLEX-MS
Description: The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
Study: NCT05356793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH-1
Description: Novel anti-infective eyedrop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SCH-1 vehicle minus active components eyedrop
Study: NCT05947019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopic amblyopia comprehensive treatment instrument
Description: Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Optometry with glasses as a routine treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Optometry with glasses as a routine treatment
Study: NCT05564403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT05087303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Types of Telemedicine Delivery Models
Description: Each arm delivers standard sickle cell care using a different model based on patient location.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Types of Telemedicine Delivery Models
Description: Each arm delivers standard sickle cell care using a different model based on patient location.
Study: NCT05675150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Arts-Based Intervention
Description: The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflection and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in intervention may seek meaning, clarity, insight and healing.
Study: NCT05636215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI354
Description: Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
Study: NCT05383807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu
Description: Six videos and eighteen reinforcer activities
Study: NCT06597396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets